Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type

Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

Alan N. Gordon, John Fleagle, David Guthrie et al. · Journal of Clinical Oncology · 2001 · 1.2K citations

Medicine, Oncology, Pharmacology +16

Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer

David G. Mutch, Mauro Orlando, T. Goss et al. · Journal of Clinical Oncology · 2007 · 441 citations · Full text

Medicine, Oncology, Pharmacology +15

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

Alan N. Gordon, Margaret Tonda, Steven Sun et al. · Gynecologic Oncology · 2004 · 431 citations

Medicine, Oncology, Pharmacology +17

Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study

Russell J. Schilder, Michael W. Sill, Xiaowei Chen et al. · Clinical Cancer Research · 2005 · 259 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

Anderley Gordon, N. Finkler, Robert P. Edwards et al. · International Journal of Gynecological Cancer · 2005 · 221 citations

Medicine, Oncology, Pharmacology +17